Nanogroup SA (NNG) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Nanogroup SA (NNG) has a cash flow conversion efficiency ratio of -0.141x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł-1.60 Million ≈ $-440.62K USD) by net assets (zł11.37 Million ≈ $3.13 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Nanogroup SA to measure how much of total assets are equity-financed.
Nanogroup SA - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Nanogroup SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Nanogroup SA cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Nanogroup SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nanogroup SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Seojin Automotive Co.Ltd
KQ:122690
|
0.107x |
|
JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares
NASDAQ:ZJYL
|
0.087x |
|
Alcom Group Bhd
KLSE:2674
|
0.069x |
|
Alpha Group International plc
LSE:ALPH
|
-0.074x |
|
Jullundur Motor Agency (Delhi) Limited
NSE:JMA
|
0.048x |
|
INTERSHOP Communications Aktiengesellschaft
XETRA:ISHA
|
0.244x |
|
Crypto Blockchain Industries SA
PA:ALCBI
|
-0.428x |
|
Iz Hayvancilik Tarim ve Gida Sanayi Ticaret AS
IS:IZINV
|
-0.336x |
Annual Cash Flow Conversion Efficiency for Nanogroup SA (2015–2024)
The table below shows the annual cash flow conversion efficiency of Nanogroup SA from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Nanogroup SA.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | zł15.93 Million ≈ $4.38 Million |
zł-5.72 Million ≈ $-1.57 Million |
-0.359x | +61.11% |
| 2023-12-31 | zł5.16 Million ≈ $1.42 Million |
zł-4.76 Million ≈ $-1.31 Million |
-0.923x | -94.91% |
| 2022-12-31 | zł7.78 Million ≈ $2.14 Million |
zł-3.68 Million ≈ $-1.01 Million |
-0.473x | -23.81% |
| 2021-12-31 | zł8.37 Million ≈ $2.30 Million |
zł-3.20 Million ≈ $-880.44K |
-0.382x | -432.65% |
| 2020-12-31 | zł18.77 Million ≈ $5.16 Million |
zł-1.35 Million ≈ $-370.81K |
-0.072x | +39.41% |
| 2019-12-31 | zł13.31 Million ≈ $3.66 Million |
zł-1.58 Million ≈ $-434.00K |
-0.118x | +47.04% |
| 2018-12-31 | zł15.52 Million ≈ $4.27 Million |
zł-3.47 Million ≈ $-955.84K |
-0.224x | -22.01% |
| 2017-12-31 | zł14.17 Million ≈ $3.90 Million |
zł-2.60 Million ≈ $-714.92K |
-0.183x | -202.75% |
| 2016-12-31 | zł12.75 Million ≈ $3.51 Million |
zł-772.07K ≈ $-212.49K |
-0.061x | -153.46% |
| 2015-12-31 | zł5.28 Million ≈ $1.45 Million |
zł-126.11K ≈ $-34.71K |
-0.024x | -- |
About Nanogroup SA
NanoGroup S.A. operates as a biotechnology company in Poland. The company develops and licenses early-stage pre-clinical and IND solutions to international biotech and pharma companies. It also manages a portfolio of companies that manages projects for the need of modern medicine in the field of oncology and transplantology. The company was incorporated in 2016 and is based in Warsaw, Poland.